Insights & Perspectives

Filter by

Therapeutic Area / Research

Year Starting

Year Ending

Search Insights:
Showing 1 to 10 of 343
Filter by: Unfiltered

White Paper | Oct 21, 2014

Pharma Industry Addresses Unmet Needs in Pain

Kantar Health explores some of the challenges affecting the pain market today, including abuse potential, recent regulatory changes, and how the gap between prevalence and treatment leads to large unmet needs.

Read more | Share

Infographic | Oct 7, 2014

Regular exercise can delay or decrease the effects of arthritis

Making healthy lifestyle choices such as exercising can help delay or decrease the effects of arthritis. Live better and age well.

Blog Post | Sep 30, 2014

The showdown between PD-1 targeted therapeutics spans several tumor types

Oncology Conference Insight: ESMO 2014 --- The role of Programmed Death-1 (PD-1) pathway in suppression of antitumor immunity has become one of the hottest topics in oncology over the past couple of years. PD-1 is a key immune checkpoint receptor expressed on activated T-cells, and binding of PD-1 to its ligand (PD-L1) results in the suppression of the immune response. While the PD-1 pathway normally plays a protective role by attenuating immune-mediated destruction of healthy tissue, the pathway can be exploited by cancer cells to protect themselves from the attack by tumor-specific T-cells.

Read more | Share

Blog Post | Sep 29, 2014

Gilotrif improves PFS in platinum-pretreated head and neck cancer, but is that enough?

Oncology Conference Insight: ESMO 2014 --- Head and neck cancer patients tend to receive chemotherapy doublets with or without the only approved targeted agent, the EGFR antibody Erbitux® (cetuximab, Bristol-Myers Squibb/Lilly/Merck Serono) as first-line therapy. Up to 90% of squamous cell carcinoma of the head and neck (SCCHN) patients have a tumor with EGFR aberrations, and according to Kantar Health’s CancerMPact® Treatment Architecture United States, in 2013 38% of chemotherapy-naïve SCCHN patients received Erbitux as part of their first-line therapy for advanced disease.

Read more | Share

Blog Post | Sep 29, 2014

CLEOPATRA: Overall survival data makes Perjeta the unmistakable queen in first-line HER2+ metastatic breast cancer

Oncology Conference Insight: ESMO 2014 --- The introduction of Herceptin® (trastuzumab, Roche/Genentech) over a decade ago turned HER2+ metastatic breast cancer (MBC) from what was once a patient population with poor prognosis to one with a vastly improved outlook and led the way for an influx of targeted therapies for this population. Now, the armamentarium against HER2+ MBC has expanded and includes several HER2-targeted agents: Tykerb® (lapatinib, GSK), Perjeta® (pertuzumab, Roche/Genentech) and Kadcyla® (ado-trastuzumab, Roche/Genentech).

Read more | Share

Datasheet | Sep 15, 2014

Value Substantiation

In the current evolving healthcare environment, precisely demonstrating the value of a compound is crucial. However, value has different definitions depending on the stakeholder. Whether it is clinical value for physicians, quality of life for patients, or direct and indirect costs for payers, value drivers are numerous and can easily overlap.

Read more | Share

Newsletter | Sep 3, 2014

Kantar Health Catalyst, September 2014

Read more | Share

Blog Post | Sep 2, 2014

Using online communities to embrace change in healthcare research

Today’s technology makes it so simple for the least tech-savvy to set up and execute an online research forum or community, yet healthcare companies are slow to embrace these opportunities to engage patients for research purposes. This blog reviews the applications and benefits of market research online communities and forums for pharma market research.

Read more | Share

Blog Post | Aug 22, 2014

Will reclassification of hydrocodone products place added burden on pain patients and the healthcare system?

Pain is a huge market. I’ve had pain, and you have too. You might be experiencing pain right now. It’s estimated that more than a billion people worldwide are dealing with pain in one form or another. It can range from acute (like a headache) to chronic (like arthritis). It can be difficult to treat because people experience pain so differently. What one person considers mild pain, another might rate as severe.

Read more | Share

Newsletter | Aug 18, 2014

Kantar Health Catalyst, August 2014

Read more | Share
Page  < 123456789 >